The Prostate Cancer Diagnosis and Therapy Market Overview and Analysis by Type (Prostate Adenocarcinoma, Small Cell Carcinoma), By Component (Therapy and Diagnosis), By End-User (Specialty Centers, Hospital & Clinics), and By Region (North America, Europe, Asia-Pacific, And Rest of The World) – Market Forecast Till 2030

Prostate Cancer Diagnosis and Therapy Market Size was valued at USD 5.9 billion in 2022 and is projected to grow from USD 6.34 Billion in 2023 to USD 10.52 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.50% during the forecast period (2023 - 2030).The report covers COVID-19 impact on the global prostate cancer diagnosis and therapy market and provides an extensive analysis of market segments, market trends, growth projections, and market challenges to identify the prevailing market opportunities.

Prostate cancer is one of the most common cancers in men over 55 years of age. More than 80% of the male population suffers from either one of the prostate cancers (prostatic adenocarcinoma, transitional cell carcinoma, sarcomas, and squamous cell carcinoma) worldwide.

Market Dynamics

Increased prevalence of prostate cancer is one of the major factors driving the market growth. Prostate cancer is the second leading cause of death in men and the fourth most common cancer in men. There is an increase in the incidence of prostate cancer due to an increasing age population, obesity, smoking, and poor dietary habits. People who consume food containing high animal fats and fewer vegetables are found to be more vulnerable to a high risk of prostate cancer. The mutation in genetic material also leads to cancer of the prostate. AGS Health in Aging Foundation, a non-profit organization, reported that approximately 3 million American men currently have prostate cancer. As per the UK World Cancer Research Fund, 1.3 million new cases of prostate cancer were identified worldwide in 2018. France, Ireland, Estonia, Barbados, Norway, and others were among the top countries with a significant number of prostate cancer cases in 2018. As a result, the increasing prevalence of cancer worldwide promotes the demand for various diagnostic and therapeutic methods.

The high cost of treatment and the side effects may impede the growth of the market. However, the launch of new products provides growth opportunities for the prostate cancer diagnosis and therapy market.

Market Segmentation

The global market for prostate cancer diagnosis and therapy is segmented into type, component, and end-user. 

By type, the global market for prostate cancer diagnosis and therapy has been segmented into prostatic adenocarcinoma, small cell carcinoma, and others. 

By product, the global prostate cancer diagnosis and therapy market share has been segmented into reagents, consumables, and analyzers.

Based on the components, the global prostate cancer diagnosis and therapy market have been classified as therapy and diagnosis. The segment for therapy is further is sub-segmented into radiotherapy drugs, hormonal therapy, chemotherapy, and immunotherapy. Hormonal therapy is divided into LHRH analogs, anti-androgens, and LHRH antagonists. Chemotherapy is divided into cabazitaxel, docetaxel, and others. The diagnosis is sub-segmented into tissue biopsy, diagnostic imaging, and others.

By the end-user, the global market for prostate cancer diagnosis and therapy has been segmented into specialty centers, hospitals & clinics, and others.

Regional Analysis

By region, the global market for prostate cancer diagnosis and therapy has been divided into the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas held the largest market share in 2018 and are likely to remain dominant during the review period due to the high prevalence rate of prostate cancer in the region, an increasing geriatric population, and an increase in early-stage treatment of prostate cancer. In addition, growing awareness of procedures related to prostate cancer diagnosis and therapy in the US is driving market growth in this area. As per the data provided by the Society, the approximate number of new cases in the US in 2019 were around 174,650 and nearly 31,620 deaths from prostate cancer (patients in treatment).

Europe is predicted to have the second-largest market share in the forecast period. Key factors, such as aging populations and growing awareness among individuals, combined with various government initiatives to promote early-stage prostate cancer treatment, are some of the major factors driving the growth of the regional market.

The Asia Pacific is expected to see the highest growth rate during the forecast period due to booming health insurance schemes, growing disposable per capita income, and the expansion of the healthcare sector in the regional market. In addition, the increase in men's obesity levels due to lifestyle changes has significantly contributed to a rise in the number of cases of prostate cancer in the region.

Key Players

The global prostate cancer diagnosis and therapy market player are Abbvie Inc. (US), Sanofi (France), AstraZeneca (UK), Ipsen Pharma (France), Astellas Pharma Inc. (Japan), Johnson & Johnson Services Inc. (US), Bayer AG (Germany), Tolmar Pharmaceuticals, Inc.(US), Dendreon Pharmaceuticals LLC (US), and Ferring BV (Switzerland), among others.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com